Steatosis during chronic hepatitis C: The role of insulin resistance and viral factors;Stéatose au cours de l'hépatite chronique C: Rôle de l'insulino-résistance et des facteurs viraux

Gastroenterologie Clinique et Biologique

Volumn 31, Issue 8-9 C1, 2007, Pages 643-654

  Moucari, Rami ^a   Marcellin, Patrick ^a   Asselah, Tarik ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CYTOKINE; FATTY ACID; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; ANTIVIRAL THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE COURSE; ENZYME ACTIVATION; FATTY LIVER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; LIPID STORAGE; LIPOGENESIS; LIPOLYSIS; LIVER CELL; LIVER FIBROSIS; METABOLIC SYNDROME X; PROTEIN EXPRESSION; PROTEIN SECRETION; SYSTEMIC DISEASE; TREATMENT RESPONSE; UPREGULATION;

EID: 34948813557     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(07)91911-9     Document Type: Article

References (111)

1. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004;126:586-97.
2. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: Why does it really matter? Gut 2006;55:123-30.
3. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004;27:2444-9.
4. Ford ES. Prevalence of the metabolic syndrome defined by the international diabetes federation among adults in the U.S. Diabetes Care 2005;28:2745-9.
5. Heckel RH, Grundy SM, Zimmet P. The metabolic syndrome. Lancet 2005;365:1415-28.
6. Alberti KG, Zimmet P, Shaw J, for the IDF epidemiology task force consensus group. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-61.
7. Khan BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000;106:473-81.
8. Sundstrom J, Riserus U, Buberg L, Zelthelius B, Lithell H, Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006;332:878-82.
9. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. Diabetes Care 2005;28:1769-78.
10. Rutter MK, Meigs JB, Sullivan LM, D'Agostino Sr. RB, Wilson PW. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham offspring study. Diabetes 2005;54:3252-7.
11. Di Bisceglie AM. What every hepatologist should know about endocrinology: obesity, diabetes, and liver. Gastroenterology 2004;126:604-6.
12. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
13. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance : insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373-9.
14. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003;37:1202-19.
15. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-25.
16. Clark JM, Brancati FL, Mae Diehl A. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-57.
17. Adams LA, Sanderson S, Lindor K, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42:132-8.
18. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100.
19. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of non alcoholic steatohepatitis from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40.
20. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-8.
21. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care 2000;23:57-63.
22. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006;131:934-45.
23. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med 2006;119:10S-16S.
24. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004;279:32345-53.
25. Koo SH, Montminy M. Fatty acids and insulin resistance: a perfect storm. Mol Cell 2006;21:449-50.
26. Bugianesi E, McCullough AJ, Marchesini G. Insulin Resistance a metabolic pathway to chronic liver disease. Hepatology 2005;42:987-1000.
27. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH : TNF-alpha or adiponectine? Hepatology 2004;40:46-54.
28. Tamori Y, Sakaue H, Kasuga M. RBP4, an unexpected adipokine. Nat Med 2006;1:30-1.
29. Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciarraldi TP, Henry RR, et al. Retinol-Binding Protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006;354:2552-63.
30. Polonsky KS. Retinol-Binding Protein 4, insulin resistance, and type 2 diabetes. N Engl J Med 2006;354:2596-8.
31. Feldestein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004;40:185-94.
32. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:147-52.
33. Monto A, Alonzo J, Watso JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002;36:729-36.
34. Lonandro A, Lombardini S, Scaglioni F, Carulli L, Ricchi M, Ganazzi D, et al. Hepatic steatosis and insulin resistance: does etiology make a difference. J Hepatol 2006;44:190-6.
35. Camma C, Bruno S, Di Marco V, Di Bona D, Rumi M, Vinci M, et al. Insulin resistance is associated with steatosis in non diabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006;43:64-71.
36. Zekry A, McHutchison JG, Diehl AM. Insulin resistance and steatosis in hepatitis C virus infection. Gut 2005;54:903-6.
37. Mehta SH, Brancati FL, Sulkowski SM, Strathdee SA, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatits C virus infection in the United States. Ann Intern Med 2000;133:592-9.
38. Lecube A, Hernandez C, Genesca J, Esteban JI, Jardi R, Simo R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection. Diabetes Care 2004;27:1171-5.
39. Zein CO, Levy C, Basu A, Zein NN. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol 2005;100:48-55.
40. Zein NN, Abdulkarim AS, Wiesner RH, Egan KS, Persing DH. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol 2000;32:209-17.
41. Petit JM, Bour JB, Galland-Jos C, Minello A, Verges B, Guiguet M, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001;35:279-83.
42. Caronia S, Taylor K, Pagliaro L, Carr C, Palazzo U, Petrik J, et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999;30:1059-63.
43. Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999;29:328-33.
44. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000;75:355-9.
45. Khalili M, Lim JW, Bass N, Ascher NL, Roberts JP, Terrault NA. New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl 2004;10:349-55.
46. Delgado-Borrego A, Casson D, Schonfeld D, Somsouk M, Terella A, Jordan SH, et al. Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 2004;77:703-10.
47. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, et al. Insulin resistance is associated with chronic hepatitis C virus infection fibrosis and progression. Gastroenterology 2003;125:1695-704.
48. Romero-Gomez M, Viloria M, Andrade R, Salmeron J, Diago M, Fernandez-Rodriguez M, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-41
49. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlosky JM. Structural biology of hepatitis C virus. Hepatology 2004;39:5-19.
50. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004;126:840-8.
51. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 2003;38:1384-92.
52. Weinman SA, Maria Belalcazar L. Hepatitis C: a metabolic liver disease. Gastroenterology 2004;126:917-9.
53. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nago Y, Ide T, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004;165:1499-508.
54. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, et al. No-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signaling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006;55:529-35.
55. Negro F. Insulin resistance and HCV. J Hepatol 2006;45:514-519.
56. Harrison SA. Correlation between insulin resistance and hepatitis C viral load. Hepatology 2006;43:1168.
57. Sanyal AJ, Chand N, Comar K, Mirshahi F. Hyperinsulinemia blocks the inhibition of hepatitis C virus (HCV) replication by interferon: a potential mechanism for failure of interferon therapy in subjects with HCV and non alcoholic fatty liver disease (abstract). Hepatology 2004;40:179A.
58. Shi ST, Polyak SJ, Tu H, Taylor DR, Gretch DR, Lai MC. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology 2002;292:198-210.
59. Barba G, Harper F, Harada T, Kohara M, Goulinet S, Mastuura Y, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci 1997;94:1200-5.
60. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002;16:185-94.
61. Abid K, Parienza V, De Gottardi A, Rubbia-Brandt L, Conne B, Pugnale P, et al. An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J Hepatol 2005;42:744-51.
62. Mirandola S, Realdon S, Iqbal J, Gerotto M, Dal Pero F, Bortoletto G, et al. Liver Microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 2006;130:1661-9.
63. Petit JM, Benichou M, Duvillard L, Jooste V, Bour JB, Minello A, et al. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am J Gastroenterol 2003;98:1150-4.
64. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004;40:484-90.
65. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64.
66. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005;54:1003-8.
67. Hézode C, Roudot Thoraval F, Zafrani E-S, Dhumeaux D, Pawlosky J-M. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. J Viral Hepatitis 2004;11:455-8.
68. Gervais A, Martinot M, Boyer N, Auperin A, Le Breton V, Degott C, et al. Quantification of hepatic hepatitis C RNA in patients with chronic hepatitis C. Relationship with severity of disease, viral genotype and response to treatment. J Hepatol 2001;35:399-405.
69. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Malé PJ, Mentha G, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000;33:106-15.
70. McGuinness PH, Bishop GA, Painter DM, Chan R, McCaughan GW. Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C. Hepatology 1996;23:676-87.
71. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002;36:1266-72.
72. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, et al. Effects of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients with hepatitis C. Hepatology 2003;38:75-85.
73. Castéra L, Hézode C, Roudot-Thoraval F, Lonjon I, Zafrani E-S, Pawlosky J-M, et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut 2004;53:420-4
74. Paradis V, Perlemuter G, Bonvust F, Dargere D, Parfait B, Vidaud M, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001;34:738-44.
75. Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T, for the LIDO Study Group. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003;39:1049-55.
76. Hickman IJ, Powell EE, Prins JB, Clouston AD, Ash S, Purdie DM, et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003;39:1042-8.
77. Muzzi A, Leandro G, Rubbia-Brandt L, James R, Keiser O, Malinverni R, et al. Insulin Resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005;42:41-6.
78. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005;100:1509-15.
79. Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002;9:2408-14.
80. Friedenberg F, Pungpapong S, Zaeri N, Braitman LE. The impact of diabetes and obesity on liver histology in patients with hepatitis C. Diabetes, Obesity and Metabolism 2003;5:150-5.
81. Hu KQ, Kyulo NL, Esrailian E, Thompson K, Chase R, Hillebrand DJ, Runyon BA. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol 2004;40:147-54.
82. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002;122:366-75.
83. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999;29:1215-9.
84. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients.J Hepatol 2002;37:837-42.
85. Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male P-J, Giostra E, et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004;53:406-12.
86. Wyatt J, Baker H, Prasad H, Gong YY, Millson C. Steatosis and fibrosis in patients with chronic hepatitis C. J Clin Pathol 2004;57:402-6.
87. Fartoux L, Chazoullieres O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005;41:82-7.
88. Asselah T, Boyer N, Guimont M-C, Cazals-Hatem D, Tubach F, Nahon K, et al. Liver fibrosis is not associated with steatosis but with necroinflammation in french patients with chronic hepatitis C. Gut 2003;52:1638-43.
89. Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003;124:97-104.
90. Perumalswami P, Kleiner DE, Lutchman G, Heller T, Borg B, Park Y, et al. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology 2006;43:780-7.
91. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Cooloredo G, et al. Relationship between steatosis, inflammation and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006;130:1636-42.
92. Negro F. Hepatitis C virus and liver steatosis: when fat is not beautiful. J Hepatol 2004;40:533-5.
93. Gale Jr M, and Foy EM. Evasion of intracellular host defense by hepatitis C virus. Nature 2005;436:939-45.
94. Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006;43:1177-86.
95. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639-44.
96. McCullough AJ. Obesity and its nurturing effect on hepatitis C. Hepatology 2003;38:557-559.
97. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Commings OW, et al. Design and validation of a histological scoring system for non alcoholic fatty liver disease. Hepatology 2005;41:1313-21.
98. Hickman IJ, Clouston AD, Macdonald GA, Purdie DM, Prins JB, Ash S, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002;51:89-94.
99. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004;53:413-19.
100. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003;38:413-19.
101. Peterson KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patents with type 2 diabetes. Diabetes 2005;54:603-8.
102. Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastro Hepatol 2006;4:639-44.
103. Sabuncu T, Nazligul Y, Karaoglanoglu M, Ucar E, Kilic FB. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance, and liver enzyme levels in obese patients with nonalcoholic steatohepatitis. Rom J Gastroenterol 2003;12:189-92.
104. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histologic analysis with weight loss. Hepatology 2004;39:1647-54.
105. Barker KB, Palekar NA, Bowers SP, Goldberg JE, Pulcini JP, Harrison SA. Non-alcoholic steatohepatitis: effect of roux-en-y gastric bypass surgery. Am J Gastroentrol 2006;101:368-73.
106. Mathurin P, Gonzalez F, Kerdraon O, Leteurtre E, Arnalsteen Hollebecque A, et al. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology. 2006;130:1617-24.
107. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda Metformin in non-alcoholic steatohepatitis. Lancet 2001;358:893-4.
108. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova et al. A randomized controlled trial of metformin versus vitamin E prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-90.
109. Lutchman G, Promrat K, Kleiner DE, Heller T, Ghany MG, Yanovski et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol 2006;4:1048-52.
110. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188-96.
111. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Olivier Bacon BR. Improves nonalcoholic steatohepatitis after 48 weeks treatment with the PPAR-gamma ligand roziglitazone. Hepatology 2003;38:1008-17.